Oui, elle peut présenter des risques pour le fœtus, nécessitant une évaluation médicale.
GrossesseÉvaluation médicale
#5
Quels sont les effets à long terme de la paroxétine ?
Les effets à long terme peuvent inclure des troubles sexuels et des changements de poids.
Effets à long termeTroubles sexuels
Facteurs de risque
5
#1
Quels facteurs augmentent le risque de dépression ?
Les antécédents familiaux, le stress chronique et les traumatismes augmentent le risque.
Facteurs de risqueAntécédents familiaux
#2
Le sexe influence-t-il le risque de troubles mentaux ?
Oui, les femmes sont souvent plus susceptibles de souffrir de dépression et d'anxiété.
SexeTroubles mentaux
#3
L'âge joue-t-il un rôle dans le risque de dépression ?
Oui, le risque peut augmenter avec l'âge, surtout chez les personnes isolées.
ÂgeIsolement social
#4
Les antécédents de troubles mentaux augmentent-ils le risque ?
Oui, les antécédents de troubles mentaux augmentent le risque de récidive.
Antécédents de troubles mentauxRécidive
#5
Le stress au travail est-il un facteur de risque ?
Oui, le stress au travail peut contribuer au développement de troubles mentaux.
Stress au travailTroubles mentaux
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Paroxétine : Questions médicales les plus fréquentes",
"headline": "Paroxétine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Paroxétine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-21",
"dateModified": "2025-12-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Paroxétine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pipéridines",
"url": "https://questionsmedicales.fr/mesh/D010880",
"about": {
"@type": "MedicalCondition",
"name": "Pipéridines",
"code": {
"@type": "MedicalCode",
"code": "D010880",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.621"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Paroxétine",
"alternateName": "Paroxetine",
"code": {
"@type": "MedicalCode",
"code": "D017374",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ahmet Yardimci",
"url": "https://questionsmedicales.fr/author/Ahmet%20Yardimci",
"affiliation": {
"@type": "Organization",
"name": "Firat University, Faculty of Medicine, Department of Physiology, Elazig, Turkey."
}
},
{
"@type": "Person",
"name": "Sinan Canpolat",
"url": "https://questionsmedicales.fr/author/Sinan%20Canpolat",
"affiliation": {
"@type": "Organization",
"name": "Firat University, Faculty of Medicine, Department of Physiology, Elazig, Turkey."
}
},
{
"@type": "Person",
"name": "Delfino Chamorro-Arenas",
"url": "https://questionsmedicales.fr/author/Delfino%20Chamorro-Arenas",
"affiliation": {
"@type": "Organization",
"name": "Laboratorio de Síntesis Orgánica, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico."
}
},
{
"@type": "Person",
"name": "Fernando Sartillo-Piscil",
"url": "https://questionsmedicales.fr/author/Fernando%20Sartillo-Piscil",
"affiliation": {
"@type": "Organization",
"name": "Laboratorio de Síntesis Orgánica, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico."
}
},
{
"@type": "Person",
"name": "Magdalena Kowalska",
"url": "https://questionsmedicales.fr/author/Magdalena%20Kowalska",
"affiliation": {
"@type": "Organization",
"name": "Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.",
"datePublished": "2023-03-30",
"url": "https://questionsmedicales.fr/article/37012633",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/FTD.0000000000001096"
}
},
{
"@type": "ScholarlyArticle",
"name": "Photodegradation fate of different dissociation species of antidepressant paroxetine and the effects of metal ion Mg",
"datePublished": "2023-06-04",
"url": "https://questionsmedicales.fr/article/37279823",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.chemosphere.2023.139070"
}
},
{
"@type": "ScholarlyArticle",
"name": "Psychological status of patients with functional anorectal pain and treatment efficacy of paroxetine in alleviating the symptoms: a retrospective study.",
"datePublished": "2023-10-21",
"url": "https://questionsmedicales.fr/article/37865675",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-45401-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Identification and investigation of depression-related molecular subtypes in inflammatory bowel disease and the anti-inflammatory mechanisms of paroxetine.",
"datePublished": "2023-02-27",
"url": "https://questionsmedicales.fr/article/36923403",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1145070"
}
},
{
"@type": "ScholarlyArticle",
"name": "The interplay of membrane fluidity, acyl chain order and area per lipid on the partitioning of two antidepressants paroxetine and sertraline.",
"datePublished": "2023-07-26",
"url": "https://questionsmedicales.fr/article/37435937",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1039/d3sm00462g"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pipéridines",
"item": "https://questionsmedicales.fr/mesh/D010880"
},
{
"@type": "ListItem",
"position": 5,
"name": "Paroxétine",
"item": "https://questionsmedicales.fr/mesh/D017374"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Paroxétine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Paroxétine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Paroxétine",
"description": "Comment diagnostiquer un trouble dépressif ?\nQuels tests sont utilisés pour évaluer l'efficacité de la paroxétine ?\nLa paroxétine est-elle efficace pour l'anxiété ?\nQuels critères sont utilisés pour prescrire la paroxétine ?\nLa paroxétine est-elle indiquée pour les troubles obsessionnels ?",
"url": "https://questionsmedicales.fr/mesh/D017374#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Paroxétine",
"description": "Quels sont les effets secondaires courants de la paroxétine ?\nLa paroxétine peut-elle provoquer des symptômes de sevrage ?\nQuels symptômes indiquent une surdose de paroxétine ?\nLa paroxétine peut-elle affecter le sommeil ?\nQuels symptômes peuvent s'améliorer avec la paroxétine ?",
"url": "https://questionsmedicales.fr/mesh/D017374#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Paroxétine",
"description": "Peut-on prévenir les troubles traités par la paroxétine ?\nQuels modes de vie favorisent la santé mentale ?\nLa thérapie peut-elle aider à prévenir la dépression ?\nLes groupes de soutien sont-ils utiles ?\nComment la gestion du stress aide-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D017374#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Paroxétine",
"description": "Comment la paroxétine est-elle administrée ?\nCombien de temps faut-il pour voir les effets de la paroxétine ?\nLa paroxétine peut-elle être combinée avec d'autres médicaments ?\nQuels sont les dosages habituels de paroxétine ?\nLa paroxétine nécessite-t-elle un suivi médical ?",
"url": "https://questionsmedicales.fr/mesh/D017374#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Paroxétine",
"description": "Quelles complications peuvent survenir avec la paroxétine ?\nLa paroxétine peut-elle provoquer des problèmes cardiaques ?\nQuels sont les risques de syndrome sérotoninergique ?\nLa paroxétine peut-elle affecter la grossesse ?\nQuels sont les effets à long terme de la paroxétine ?",
"url": "https://questionsmedicales.fr/mesh/D017374#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Paroxétine",
"description": "Quels facteurs augmentent le risque de dépression ?\nLe sexe influence-t-il le risque de troubles mentaux ?\nL'âge joue-t-il un rôle dans le risque de dépression ?\nLes antécédents de troubles mentaux augmentent-ils le risque ?\nLe stress au travail est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D017374#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un trouble dépressif ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur l'évaluation des symptômes et l'historique médical."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité de la paroxétine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échelles d'évaluation des symptômes et des entretiens cliniques sont utilisés."
}
},
{
"@type": "Question",
"name": "La paroxétine est-elle efficace pour l'anxiété ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est souvent prescrite pour traiter les troubles anxieux."
}
},
{
"@type": "Question",
"name": "Quels critères sont utilisés pour prescrire la paroxétine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent la sévérité des symptômes et les antécédents médicaux."
}
},
{
"@type": "Question",
"name": "La paroxétine est-elle indiquée pour les troubles obsessionnels ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est souvent utilisée pour traiter les troubles obsessionnels compulsifs."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants de la paroxétine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets incluent nausées, somnolence, et troubles sexuels."
}
},
{
"@type": "Question",
"name": "La paroxétine peut-elle provoquer des symptômes de sevrage ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un sevrage brusque peut entraîner des symptômes tels que vertiges et irritabilité."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose de paroxétine ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent confusion, agitation, et tachycardie."
}
},
{
"@type": "Question",
"name": "La paroxétine peut-elle affecter le sommeil ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut causer des troubles du sommeil comme l'insomnie ou la somnolence."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent s'améliorer avec la paroxétine ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes de dépression, d'anxiété et de troubles obsessionnels peuvent s'améliorer."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles traités par la paroxétine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut la gestion du stress et le soutien psychologique."
}
},
{
"@type": "Question",
"name": "Quels modes de vie favorisent la santé mentale ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice régulier et le sommeil suffisant favorisent la santé mentale."
}
},
{
"@type": "Question",
"name": "La thérapie peut-elle aider à prévenir la dépression ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie cognitive et comportementale peut réduire le risque de dépression."
}
},
{
"@type": "Question",
"name": "Les groupes de soutien sont-ils utiles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils offrent un soutien émotionnel et des stratégies de coping."
}
},
{
"@type": "Question",
"name": "Comment la gestion du stress aide-t-elle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle réduit l'anxiété et améliore le bien-être général, diminuant le risque de troubles."
}
},
{
"@type": "Question",
"name": "Comment la paroxétine est-elle administrée ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est généralement administrée par voie orale sous forme de comprimés."
}
},
{
"@type": "Question",
"name": "Combien de temps faut-il pour voir les effets de la paroxétine ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets peuvent être ressentis après 2 à 4 semaines de traitement."
}
},
{
"@type": "Question",
"name": "La paroxétine peut-elle être combinée avec d'autres médicaments ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, mais cela doit être fait sous supervision médicale pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Quels sont les dosages habituels de paroxétine ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les dosages varient de 20 à 50 mg par jour, selon l'indication."
}
},
{
"@type": "Question",
"name": "La paroxétine nécessite-t-elle un suivi médical ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour ajuster le traitement et surveiller les effets."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la paroxétine ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles de la coagulation et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "La paroxétine peut-elle provoquer des problèmes cardiaques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans de rares cas, elle peut entraîner des problèmes cardiaques, surtout à forte dose."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de syndrome sérotoninergique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le syndrome sérotoninergique peut survenir avec des doses élevées ou des interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "La paroxétine peut-elle affecter la grossesse ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut présenter des risques pour le fœtus, nécessitant une évaluation médicale."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme de la paroxétine ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme peuvent inclure des troubles sexuels et des changements de poids."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de dépression ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le stress chronique et les traumatismes augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de troubles mentaux ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes sont souvent plus susceptibles de souffrir de dépression et d'anxiété."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans le risque de dépression ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge, surtout chez les personnes isolées."
}
},
{
"@type": "Question",
"name": "Les antécédents de troubles mentaux augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de troubles mentaux augmentent le risque de récidive."
}
},
{
"@type": "Question",
"name": "Le stress au travail est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress au travail peut contribuer au développement de troubles mentaux."
}
}
]
}
]
}
Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland.
Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland.
Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland.
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy. Electronic address: roberto.melcangi@unimi.it.
Life Sciences Institute (R.A.B., H.V.W.), Departments of Medicinal Chemistry (H.V.W., S.D.L.) and Pharmacology (R.A.B., Z.Y.W., M.A.P.), and Vahlteich Medicinal Chemistry Core, College of Pharmacy (H.V.W., S.D.L.), University of Michigan, Ann Arbor, Michigan; and Departments of Biological Sciences and of Medicinal Chemistry and Molecular Pharmacology (Y.-C.Y., J.J.G.T.), Purdue University, West Lafayette, Indiana jtesmer@purdue.edu.
Paroxetine is a selective serotonin reuptake inhibitor metabolized by cytochrome P450 (CYP)2D6. Only small-scale studies have reported the impact of CYP2D6 genotype on paroxetine exposure, and interna...
Patients from a therapeutic drug monitoring database with records on their paroxetine serum concentrations and CYP2D6 and CYP2C19 genotyping between 2010 and 2021 were included in the study. The impac...
In total, 304 patients were included in the study: 17 CYP2D6 poor metabolizers (PMs), 114 intermediate metabolizers (IMs), 168 extensive metabolizers (EMs), and 5 ultrarapid metabolizers. Multiple lin...
The present study showed that CYP2D6 genotype is of significant importance for paroxetine dose adjustments. For CYP2D6 PMs, 25% of the regular paroxetine starting dose may be sufficient, whereas CYP2D...
Paroxetine (abbreviated as PXT) has been widely used as one of the standard antidepressants for the treatment of depression. PXT has been detected in the aqueous environment. However, the photodegrada...
The aim of this study was to investigate the clinical characteristics, psychological status, sleep quality, and quality of life of patients with functional anorectal pain (FAP). The study also assesse...
Up to 40 per cent of people with active inflammatory bowel disease (IBD) also suffer from mood disorders such as anxiety and depression. Notwithstanding, the fundamental biological pathways driving de...
We identified 33 core genes that drive depression in IBD patients and performed consensus molecular subtyping with the NMF algorithm in IBD. The CIBERSORT were employed to quantify the immune cells. M...
Using transcriptome data from the GEO database of 630 IBD patients, we performed a thorough analysis of the correlation between IBD and depression in this research. Firstly, the samples were separated...
This study highlights that IBD patients with or without depression show significant variations and antidepressant paroxetine may help reduce intestinal inflammation....
Selective serotonin reuptake inhibitors (SSRIs) are among the popular drugs for treating depression and mental disorders. Membrane fluidity has previously been considered as the main factor in modulat...
Patients with refractory erythema of rosacea have limited treatment options....
To evaluate the efficacy and safety of a 12-week course of paroxetine for moderate-to-severe erythema of rosacea....
In a multicenter, randomized, double-blinded, placebo-controlled trial, patients with refractory erythema of rosacea were randomly assigned (1:1) to receive paroxetine 25 mg daily or placebo for 12 we...
Overall, 97 patients completed the study (paroxetine: 49; placebo: 48). The primary end point was the proportion of participants achieving Clinical Erythema Assessment success (defined as Clinical Ery...
Only a single-dosage regimen of paroxetine within a 12-week study was evaluated....
Paroxetine is an effective and well-tolerated alternative treatment for moderate-to-severe erythema of rosacea....
Desvenlafaxine (O-desmethylvenlafaxine) and paroxetine are antidepressants that inhibit serotonin reuptake. Despite their relatively safe profiles, several serious side effects, including serotonin sy...
Post-traumatic stress disorder (PTSD) is a mental disorder that can emerge after an individual experiences a traumatic event such as physical abuse, sexual/relationship violence, combat exposure, witn...
Six databases (Ovid Medline, EMBase, CENTRAL, PsycINFO, Ovid Health and Psychosocial Instruments, and Web of Science) were searched from inception to September 6, 2022....
Thirty articles with a total of 5170 participants were included. Compared with placebo, active drugs including olanzapine (SMD = -0.66, 95% CI: -1.19 to -0.13), risperidone (SMD = -0.23, 95% CI: -0.42...
The results of this study support the use of paroxetine, venlafaxine, and quetiapine as first-line treatment for PTSD. In addition, quetiapine is recommended for patients with PTSD affected by symptom...
A panic attack is a discrete period of fear or anxiety that has a rapid onset and reaches a peak within 10 minutes. The main symptoms involve bodily systems, such as racing heart, chest pain, sweating...
To compare, via network meta-analysis, individual drugs (antidepressants and benzodiazepines) or placebo in terms of efficacy and acceptability in the acute treatment of panic disorder, with or withou...
We searched the Cochrane Common Mental Disorders Specialised Register, CENTRAL, CDSR, MEDLINE, Ovid Embase and PsycINFO to 26 May 2022....
We included randomised controlled trials (RCTs) of people aged 18 years or older of either sex and any ethnicity with clinically diagnosed panic disorder, with or without agoraphobia. We included tria...
Two authors independently screened titles/abstracts and full texts, extracted data and assessed risk of bias. We analysed dichotomous data and continuous data as risk ratios (RRs), mean differences (M...
Overall, we included 70 trials in this review. Sample sizes ranged between 5 and 445 participants in each arm, and the total sample size per study ranged from 10 to 1168. Thirty-five studies included ...
In terms of efficacy, SSRIs, SNRIs (venlafaxine), TCAs, MAOIs and BDZs may be effective, with little difference between classes. However, it is important to note that the reliability of these findings...
Ulotaront is a novel psychotropic agent with agonist activity at trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT...
This study aimed to investigate the effect of paroxetine, a strong cytochrome P450 (CYP) 2D6 inhibitor, on ulotaront pharmacokinetics (PK) in healthy volunteers....
Subjects received a single oral dose of 25 mg ulotaront on Day 1 and an oral dose of 20 mg paroxetine once daily from Days 5 to 10 to achieve steady-state plasma paroxetine levels. On Day 11, subjects...
Coadministration of paroxetine increased ulotaront maximum observed plasma concentration (C...
Weak drug-drug interactions were observed between ulotaront and the strong CYP2D6 inhibitor paroxetine; however, dose adjustment as a precondition when ulotaront is coadministered with strong CYP2D6 i...